Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Bivalirudin (Angiomax) Peptide
Direct thrombin inhibitor peptide for PCI anticoagulation.
What is Bivalirudin (Angiomax)?
Bivalirudin (Angiomax) is a anticoagulant · cardiology peptide studied for pci anticoagulation and heparin-induced thrombocytopenia. Below is an educational overview of Bivalirudin (Angiomax) peptide benefits, mechanism, common research protocols, dosage references, and known side effects.
Plain-Language Label Highlights
Brand names: Angiomax, Angiox
Anticoagulation during percutaneous coronary intervention (PCI) and certain heart procedures.
A short-acting IV blood thinner used during heart-artery procedures as an alternative to heparin.
- •Bleeding (most common)
- •Back pain
- •Nausea
- •Low blood pressure
- •Major bleeding
- •Acute stent thrombosis (rare)
- •Active major bleeding
- •Severe uncontrolled hypertension
Educational summary of the FDA prescribing information. Not a substitute for the full label or medical advice. Always discuss with a licensed prescriber.
Bivalirudin (Angiomax) Mechanism of Action
Synthetic 20-amino-acid peptide that reversibly and directly inhibits thrombin (both circulating and fibrin-bound). Used for anticoagulation during percutaneous coronary intervention.
Bivalirudin (Angiomax) Research Areas & Benefits
Bivalirudin (Angiomax) Dosage & Common Research Protocols
0.75 mg/kg IV bolus + 1.75 mg/kg/h infusion during procedure.
Protocols summarized for educational reference from published research. Not dosing guidance.
Bivalirudin (Angiomax) Studies & Cited Research
HORIZONS-AMI trial
Reduced bleeding vs heparin + GP IIb/IIIa in primary PCI.
Why we trust this source: Published in a peer-reviewed scientific journal with editorial and reviewer oversight.
Citations are linked to PubMed, Google Scholar, and Crossref searches so you can verify the source independently. All references are reviewed during our editorial passes (last reviewed June 1, 2026).
Bivalirudin (Angiomax) Side Effects & Safety Considerations
- •FDA-approved.
- •Renal dose adjustment required.
Explore more peptides
Educational Information Only — Not Medical Advice
All content on this page is for educational and informational purposes only. It is not medical advice, diagnosis, or treatment. We make no claims that any peptide can diagnose, treat, cure, or prevent any disease. Peptides discussed are not FDA-approved for the indications listed unless explicitly stated otherwise.
Always consult a licensed healthcare provider before beginning any wellness protocol. Statements have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability, eligibility, and pricing may vary.
Ask the Library
Ask anything about peptides — answers come from our curated reference library with citations.